Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-6913
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MK-6913 is a potent and selective small molecule agonist of the estrogen receptor beta (ERβ). It was developed as a non-hormonal treatment for vasomotor symptoms (hot flashes) in postmenopausal women. The drug acts by selectively activating ERβ, which is thought to mediate beneficial effects on vasomotor symptoms without the risks associated with estrogen receptor alpha activation. MK-6913 originated from a collaboration between Karo Bio and Merck & Co., but its development was discontinued after Phase II trials failed to meet efficacy criteria for hot flash reduction[1][5][7].
- Other names
- MK 6913MK6913MK-6913Tetrahydrofluoroene 52Tetrahydrofluoroene52Tetrahydrofluoroene-52
02
Targets
ESR2 (ERβ)
Beyond the preview
Go deeper on MK-6913.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-6913.